Principles of Anticancer Drug Development

Editors:

ISBN: 978-1-4419-7357-3 (Print) 978-1-4419-7358-0 (Online)

Table of contents (23 chapters)

previous Page of 2
  1. Front Matter

    Pages i-xvii

  2. Part I

    1. Front Matter

      Pages 1-1

    2. No Access

      Book Chapter

      Pages 3-35

      Basic Biostatistics for the Clinical Trialist

    3. No Access

      Book Chapter

      Pages 37-62

      Fundamental Concepts in Clinical Pharmacology

    4. No Access

      Book Chapter

      Pages 63-86

      Bioanalytical Methods in Clinical Drug Development

  3. Part II

    1. Front Matter

      Pages 87-87

    2. No Access

      Book Chapter

      Pages 89-114

      Preclinical Models for Anticancer Drug Development

  4. Part III

    1. Front Matter

      Pages 115-115

    2. No Access

      Book Chapter

      Pages 117-139

      Phase I Clinical Trials with Anticancer Agents

    3. No Access

      Book Chapter

      Pages 141-161

      Phase II Trials with Anticancer Agents

    4. No Access

      Book Chapter

      Pages 163-188

      Phase III Clinical Trials with Anticancer Agents

    5. No Access

      Book Chapter

      Pages 189-214

      Pharmacokinetic Studies in Early Anticancer Drug Development

    6. No Access

      Book Chapter

      Pages 215-256

      Pharmacodynamic Studies in Early Phase Drug Development

    7. No Access

      Book Chapter

      Pages 257-274

      Prediction of Antitumor Response

    8. No Access

      Book Chapter

      Pages 275-302

      Imaging Studies in Anticancer Drug Development

  5. Part IV

    1. Front Matter

      Pages 303-303

    2. No Access

      Book Chapter

      Pages 305-332

      Role of the US Food and Drug Administration in Cancer Drug Development

  6. Part V

    1. Front Matter

      Pages 333-333

    2. No Access

      Book Chapter

      Pages 335-345

      Early Clinical Trials with Cytotoxic Agents

    3. No Access

      Book Chapter

      Pages 347-401

      Challenges and Successes in Developing Effective Anti-angiogenic Agents

    4. No Access

      Book Chapter

      Pages 403-461

      Targeted Therapeutics in Cancer Treatment

    5. No Access

      Book Chapter

      Pages 463-481

      Cancer Chemoprevention

    6. No Access

      Book Chapter

      Pages 483-517

      Combined Modality Therapy in Cancer Management

    7. No Access

      Book Chapter

      Pages 519-533

      Cancer Vaccines

    8. No Access

      Book Chapter

      Pages 535-567

      Optimising the Development of Antibodies as Treatment for Cancer

    9. No Access

      Book Chapter

      Pages 569-587

      Oligonucleotide Therapeutics

previous Page of 2